Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma
Article 2015 en
Authors
TA
Tadaaki Arizumi
KU
Kazuomi Ueshima
TM
Tomohiro Minami
Abstract
1 min read
Conversion to sorafenib significantly improves the OS in patients refractory to TACE therapy with intermediate-stage HCC. Administration of sorafenib is therefore recommended in such circumstances of TACE treatment failure.
Riccardo Lencioni, Josep M. Llovet, Guohong Han, Won Young Tak, Jiamei Yang, Alfredo Guglielmi, Seung Woon Paik, María Reig, Do Young Kim, Gar-Yang Chau, Angelo Luca, L Ruíz del Arbol, Marie-Aude LeBerre, Woody Niu, Kate Nicholson, Gerold Meinhardt, Jordi Bruix
Discussion(0)
No comments yet. Be the first to comment.